Celgene-partnered biotech Inhibrx has had a busy 2019 so far. The La Jolla, California-based company kicked off an early-stage oncology study, partnered with Bluebird bio, signed a pact with Italy?s Chiesi Group and secured a $40 million venture capital injection. On Monday, it laid the groundwork for a roughly $75 million IPO.
Inhibrx is developing a plethora of biologics ? it has three oncology programs in human clinical trials, a rare disease program, for which it expects to initiate a human study in the third quarter of 2019, as well as two preclinical drugs.
Its lead experimental drug targets death receptor 5, or DR5, and is designed to treat multiple tumor types, including difficult-to-treat gastrointestinal tumors and mesothelioma both as a monotherapy and in combination with chemotherapy. It is currently being investigated in an early stage trial in patients with solid tumors including sarcomas, and the readout of that study is expected in the second half of th